PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsYoichi Nagata, Dihua Yu, Keng‐Hsueh Lan et al.|Cancer Cell|2004Cited by 1.9k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian CancersCatharine M. Sturgeon, Eleftherios P. Diamandis, George G. Klee et al.|Clinical Chemistry|2008Cited by 1.1k
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsEun‐Jung Jung, George A. Călin, Libero Santarpia et al.|Cancer|2011Cited by 291
PTEN, PIK3CA, p-AKT, and p-p70S6K StatusFrancisco J. Esteva, Dihua Yu|American Journal Of Pathology|2010Cited by 285
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based TherapyPhuong K. Morrow, Francisco J. Esteva|Journal of Clinical Oncology|2011Cited by 211